A Study of Isoprinosine in Patients With Lymph Node Disease
يمكن للمستخدمين المسجلين فقط ترجمة المقالات
الدخول التسجيل فى الموقع
يتم حفظ الارتباط في الحافظة
الحالةمنجز
الرعاة
Newport Pharmaceuticals International
تجربة سريرية: NCT00002297
BioSeek: nct00002297
الكلمات الدالة
نبذة مختصرة
The objectives of this study are to determine the effects of isoprinosine in patients diagnosed as having unexplained generalized lymphadenopathy. Variables to be examined will include:
Signs and symptoms:
- Lymphadenopathy.
- Fever.
- Weight loss.
- Occurrence of opportunistic infections.
Cell-mediated immune system parameters:
- T-helper cell (OKT4) numbers and proportions.
- T-suppressor cell (OKT8) numbers and proportions.
- Natural killer (NK) cell activity.
- Lymphocyte blastogenic response to phytohemagglutinin (PHA).
- Lymphocyte blastogenic response to pokeweed mitogen (PWM).
- Immunoglobulin (IgG, IgA, IgM, IgE, IgD) profile.
- Circulating immune complexes. Infections characteristically associated with AIDS, such as Candida albicans, Pneumocystis carinii pneumonia, Cytomegalovirus, Herpes simplex, Cryptococcus, Histoplasma, Toxoplasma, Cryptosporidium, Mycobacterium avium- intracellulare, Legionella, and Isospora.
Safety parameters:
- Blood chemistry including serum uric acid (PurposeA-12).
- Complete blood count (CBC).
- Platelet count.
تواريخ
| آخر التحقق: | 05/31/1989 |
| تم الإرسال لأول مرة: | 11/01/1999 |
| تم إرسال التسجيل المقدر: | 08/29/2001 |
| أول نشر: | 08/30/2001 |
| تم إرسال آخر تحديث: | 06/22/2005 |
| آخر تحديث تم نشره: | 06/23/2005 |
حالة أو مرض
Lymphatic Disease
HIV Infections
التدخل / العلاج
Drug: Inosine pranobex
مرحلة
-
معايير الأهلية
| الأعمار المؤهلة للدراسة | 18 Years إلى 18 Years |
| الأجناس المؤهلة للدراسة | Male |
| يقبل المتطوعين الأصحاء | نعم |
| المعايير | Exclusion Criteria Co-existing Condition: Patients with a history of gout, uric acid urolithiasis, uric acid nephrolithiasis, renal dysfunction, or gastric ulceration are excluded. Concurrent Medication: Excluded: - Systemic corticosteroids. - Cytotoxic immunosuppressive agents. - Radiotherapy. Critically ill patients or those with CDC-defined AIDS are excluded. Prior Medication: Excluded within 1 month of study entry: - Immunotherapy. Patients with persistent generalized lymphadenopathy (PGL). |
